We appreciate the support offered in the letter by Drs Mitchell, Newth, and Joffe. We are hopeful that continued questioning of the recently published guidelines on the use of ribavirin for respiratory syncytial virus infection will lead to a change in the recommendations.

This content is only available via PDF.
You do not currently have access to this content.